Evaluating telephone calls to help glaucoma patients

July 12, 2012

(Medical Xpress) -- Interactive telephone calls and tailored print materials helped glaucoma patients adhere to their treatment better, but not significantly as compared with a control group. The report on a randomized controlled clinical trial was published online first by the Archives of Ophthalmology, a JAMA Network publication.

A 2006-10 study, the Interactive Study to Increase adHerence to Treatment (I-SIGHT), was initiated to try and help non-compliant patients adhere to glaucoma treatment goals. Funded through the National Eye Institute (NEI)/National Institutes of Health (NIH), the study proposed to develop, implement, and evaluate an innovative e- intervention to improve glaucoma treatment compliance among more than 300 patients recruited from two eye clinics in Atlanta.

The intervention was telephone-based and utilized interactive . It was individually-tailored to participants’ compliance knowledge, attitudes, and behaviors; health literacy; race and culture; and prescribed medication regimen. Its hope was to have a significant impact on public health by testing a generalizable and affordable health promotion strategy to increase treatment compliance among diverse populations.

Susan Primo, OD, MPH, Emory Eye Center’s director of Vision & Optical Services and a co-investigator, got the I-SIGHT study off the ground when she teamed up with colleagues at Emory’s Rollins School of Public Health, including Jay Bernhart, PhD, MPH. Ultimately, Karen Glanz, PhD, MPH, then at Rollins, secured needed NEI funding for the study.

“The idea for a study stemmed from my work and observations in the Grady Health System,” says Primo. “Along with the problem with adherence and compliance for glaucoma therapy, the idea of how we communicate effectively with patients was intriguing, and this study helped us know a little better how that might be done.”

“The I-SIGHT study is the largest and longest study to date on an intervention strategy to improve glaucoma adherence,” says Allen Beck, MD, principal investigator (PI) at Emory and section chief of glaucoma. “It may be easier to improve adherence to and appointment attendance than was previously thought. We hope that our study will prove useful to clinicians and researchers who are attempting to improve compliance with glaucoma therapy.”

Glanz, director of the Emory Prevention Research Center (EPRC) at the Rollins School of Public Health until 2009, was principal investigator at Emory prior to joining the University of Pennsylvania, Philadelphia. At her departure, Beck became the PI at Emory.

Glanz and colleagues enrolled 312 patients with glaucoma in a randomized controlled trial at two eye clinics at a Veterans Affairs hospital and a large public hospital, Atlanta’s Grady Hospital. The patients (average age nearly 63 years) were considered to be non-adherent because they did not take their medication, refill their medicine and/or keep their medical appointments.

Patients were divided into either the treatment or . The treatment group received automated, interactive telephone calls and tailored printed materials, while the control group received usual care, which included the recommendation for medical appointments and medication refills. Researchers measured adherence to medication taking, prescription refills and appointment keeping based on interviews, medical charts and other data.

“A statistically significant increase for all adherence measures was noted in both the treatment group and the control group in the I-SIGHT (Interactive Study to Increase Glaucoma Adherence to Treatment) trial. The treatment group had greater improvements in adherence in 4 of 6 categories, but this did not reach statistical significance,” the authors comment.

Researchers suggest that “motivated patients” in an ongoing clinical trial might improve their treatment adherence even without tailored messages for encouragement.

Glaucoma affects more than 2.2 million adults over the age of 40 in the United States. It is the second leading cause of blindness in the world, according to the World Health Organization. Medication prescribed early on can reduce the visual field loss caused by glaucoma, a progressive disease.

It is crucial that patients take their glaucoma medication and follow up with appropriate medical appointments, as the devastating effects of glaucoma are not seen until the later stages of the disease. Glaucoma reduces peripheral vision, and those who have it often don’t know it. Glaucoma should be detected early in order to stop the progression of the disease. Dilated eye exams are important in detecting glaucoma.

Explore further: Study examines telephone intervention in glaucoma treatment adherence

More information: Ref: (Arch Ophthalmol. Published online June 11, 2012. doi:10.1001/archophthalmol.2012.1607.

Related Stories

World-first glaucoma gene discovery

May 2, 2011

(Medical Xpress) -- An Australian research team led by Flinders University researchers has discovered two new genes that could open the way to new treatments for blinding glaucoma.

Recommended for you

A pocket-sized retina camera, no dilating required

March 20, 2017

It's the part of the eye exam everyone hates: the pupil-dilating eye drops. The drops work by opening the pupil and preventing the iris from constricting in response to light and are often used for routine examination and ...

Scientists deploy CRISPR to preserve photoreceptors in mice

March 14, 2017

Silencing a gene called Nrl in mice prevents the loss of cells from degenerative diseases of the retina, according to a new study. The findings could lead to novel therapies for preventing vision loss from human diseases ...

New help for that bane of middle-age: blurry close-up vision

February 28, 2017

Squinting while texting? Always losing your reading glasses? An eye implant that takes about 10 minutes to put in place is the newest in a list of surgical repairs for the blurry close-up vision that is a bane of middle age. ...

Vitamin B3 prevents glaucoma in laboratory mice

February 16, 2017

In mice genetically predisposed to glaucoma, vitamin B3 added to drinking water is effective at preventing the disease, a research team led by Jackson Laboratory Professor and Howard Hughes Medical Investigator Simon W.M. ...

GARP2 accelerates retinal degeneration in a mouse model

February 15, 2017

In the retina of the eye, rod and cone cells turn light into electrical signals, the first step toward human vision. University of Alabama at Birmingham researchers are studying rod cell proteins GARP1 and GARP2 to learn ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.